Topic : New drugs

Other Topics :

Updated results for Synribo in CML

February marks the anniversary of the U.S. FDA’s approval of Synribo (omacetaxine) for the treatment of chronic myelogenous leukemia, and longer-term results have just been published.
Continue Reading →

New CML drug gets full approval in U.S.: omacetaxine

The latest addition to the arsenal of CML medications is omacetaxine (SYNRIBO), which the FDA grant full approval to in February 2014.
Continue Reading →

The see-saw story of Iclusig

Three TKIs are widely available to treat CML (Gleevec, Tasigna and Sprycel), and a fourth (Bosulif) has been approved in the U.S. and Europe.
Continue Reading →